May 14, 2013, 06.10 PM | Source: CNBC-TV18
One can hold Dr Reddys Laboratories, says Prakash Diwan, Chief Portfolio Strategist of Prakash Diwan's Wealth Circle, ECR.
Prakash Diwan (more)
Market Expert, prakashdiwan.in | Capital Expertise: Equity - Fundamental
He further added, "The best point is the valuations, I don’t think valuations are stretched as compared to Sun Pharma or a Cipla or a Lupin relatively. I think the investor should hold on. Wait for another 20-25 percent of an upside in the next 9 to 12 months if the investor is patient enough."
Net Sales are expected to increase by 0.4 percent
US Food and Drug Administration (USFDA) will re-au
Nomura has a buy ratings on Dr Reddy’s, Glenmark
Gaurang Shah of Geojit BNP Paribas advises buying